SPR Therapeutics has received Food and Drug Administration (FDA) clearance for an update of its wearable Sprint Peripheral Nerve Stimulation pain management device. SPR Therapeutics’ percutaneous electrical nerve stimulator is a non-narcotic alternative for chronic and acute pain relief indicated for up to 60 days of use in the back or extremities. The Ohio-based company said the device would now be available as single or dual lead, able to use rechargeable batteries, and be Bluetooth-enabled. “Today’s FDA approval is a major milestone in our efforts to bring new therapies into clinical use,” said Dr. David L. Brown, CEO of Sprint. It can be used for up to 60 days. SPR said the placement was reversible and would be ideal for shorter outpatient procedures.
SPR Therapeutics has received Food and Drug Administration (FDA) clearance for an update of its wearable Sprint Peripheral Nerve Stimulation pain management device. The Ohio-based company said the device would now be available as single or dual lead, able to use rechargeable batteries, and be Bluetooth-enabled. “Today’s FDA approval is a major milestone in our efforts to bring new therapies into clinical use,” said Dr. David L. Brown, CEO of Sprint. It can be used for up to 60 days. SPR said the placement was reversible and would be ideal for shorter outpatient procedures.